Erasca is a clinical-stage, precision oncology company with a bold mission—to erase cancer. We are focused on the discovery, development and commercialization of novel therapies and combination regimens designed to comprehensively shut down cancer’s most commonly mutated signaling cascade, the RAS/MAPK pathway, linked to approximately 5.5 million new cases of cancer per year worldwide, over 90% of which have limited or no treatment options. Our robust, rapidly advancing pipeline of promising therapeutic candidates has the potential to improve the treatment of a range of RAS/MAPK pathway-related cancers—and in turn, transform millions of lives.


Latest Presentation

More information is coming soon.